Poseida Therapeutics | IPO Presentation Deck | 34 slides

Poseida Therapeutics · 2020-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

34
every slide · same image gating as the playbook
01
Slide 1
The word cloud contains key company themes like 'Early memory stem cell', 'CAR-T', 'Allogenic', 'Oncology', and 'Curative'.front_matter
03
This is a standard IPO/follow-on offering summary table.plan_implementation
04
Slide 3 of a pitch deck.establish_context
Open slide detailBeat · ProblemLoop · Golden Circle
05
The slide acts as a high-level summary of the company's value proposition and asset structure.summarize
Open slide detailBeat · ProblemLoop · Golden Circle
06
The slide uses a modular framework to categorize the company's technological stack.present_solution
Open slide detailBeat · Solution
07
The diagram illustrates the 'cut and paste' mechanism of the transposon system.present_solution
Open slide detailBeat · Solution
08
The slide uses a visual metaphor of combining two existing technologies to create a superior third one.present_solution
Open slide detailBeat · Solution
09
The slide uses a spectrum-style diagram to categorize delivery methods.present_solution
Open slide detailBeat · Solution
10
The slide uses a categorization framework to map competitors against specific therapeutic modalities (Cell Therapies, Gene Therapies, Other).compare_peers
Open slide detailBeat · Market Size
11
The slide uses a Gantt-style chart to represent clinical trial progress for various oncology and gene therapy candidates.plan_implementation
Open slide detailBeat · Product
12
transition
Open slide detailBeat · Product
13
The slide uses a process diagram to show cell differentiation and a callout box to list clinical benefits.present_solution
Open slide detailBeat · ProductLoop · Cost Of Inaction
14
present_solution
Open slide detailBeat · ProductLoop · Cost Of Inaction
15
The slide highlights clinical trial results for an autologous product as a stepping stone to allogeneic development.show_traction
Open slide detailBeat · Product
16
Uses patient success stories as clinical evidence of product efficacy.show_traction
Open slide detailBeat · Product
17
Includes a process flow diagram and a specific technical callout for Cas-CLOVER gene editing.present_solution
Open slide detailBeat · Product
18
The slide uses a biological diagram to explain the mechanism of T-cell activation and a line chart to show the performance improvement.present_solution
Open slide detailBeat · Product
19
The slide uses two distinct chart types (bar and dot plot) to highlight two key performance metrics of the technology.present_solution
Open slide detailBeat · Product
20
The slide compares autologous (101) vs allogeneic (ALLO1) CAR-T therapy efficacy in tumor reduction.show_traction
Open slide detailBeat · Product
21
Slide 20 of a pitch deck, showing longitudinal efficacy data.show_traction
Open slide detailBeat · Product
22
Uses a before-after framing to contrast standard multi-dose therapy with the company's single-dose, self-renewing approach.present_solution
Open slide detailBeat · Product
23
Data presented at SITC 2017. Includes both imaging and caliper measurement data.show_traction
Open slide detailBeat · Product
24
The slide uses a quadrant key to identify T-cell subsets (Teff, TSCM, Tem, Tcm) and highlights the persistence of TSCM cells post-tumor elimination.show_traction
Open slide detailBeat · Product
25
The slide uses a combination of a table for market potential, a biological diagram for mechanism, and bar charts for efficacy and safety.present_solution
Open slide detailBeat · Product
26
The slide uses two line charts to demonstrate efficacy across two different cancer models.show_traction
27
The slide highlights the technical advantage of the piggyBac system in delivering multiple genes for multi-target CAR-T therapies.present_solution
28
transition
29
The slide uses a two-column layout to contrast technical capability (PiggyBac) with market breadth (indications).present_solution
30
The slide contrasts the persistence of integrated transposons versus the clearance of non-integrated AAV following liver cell replication.present_solution
31
Includes histological images, a dot plot for OTC activity, and a Kaplan-Meier survival curve.show_traction
32
The slide uses a comparative framework to show the efficacy of the non-viral approach.present_solution
33
The slide uses a modular layout to categorize the company's technology platforms and therapeutic pipeline.present_solution
34
The word cloud uses a spiral motif to emphasize key terms like 'Tscm', 'CAR-T', 'Autologous', and 'Curative'.front_matter